Immunoinformatics-based potential multi-peptide vaccine designing against Jamestown Canyon Virus (JCV) capable of eliciting cellular and humoral immune responses

Shahab, Muhammad; Aiman, Sara; Alshammari, Abdulrahman; Alasmari, Abdullah F.; Alharbi, Metab; Khan, Abbas; Wei, Dong-Qing; Zheng, Guojun

doi:10.1016/j.ijbiomac.2023.126678

Cited by 12 publications

(7 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reverse vaccinology is a promising method for vaccine development. Previous research have resulted in the development of vaccines through the process of reverse vaccinology, which involves the production of vaccine against Jamestown canyon virus, 49 hepatitis C virus, 50 monkeypox virus, 51 chikungunya virus, 52 Burkholderia pseudomallei, 53 and lumpy skin disease. 54 The immunoinformatics prediction results have also been tested for validity both in vivo and in vitro.…”

Section: Resultsmentioning

confidence: 99%

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Rizarullah,

Aditama,

Giri-Rachman

et al. 2024

ACS Omega

View full text Add to dashboard Cite

One of the deadliest malignant cancer in women globally is cervical cancer. Specifically, cervical cancer is the second most common type of cancer in Indonesia. The main infectious agent of cervical cancer is the human papilloma virus (HPV). Although licensed prophylactic vaccines are available, cervical cancer cases are on the rise. Therapy using multiepitope-based vaccines is a very promising therapy for cervical cancer. This study aimed to develop a multiepitope vaccine based on the E1 and E2 proteins of HPV 16, 18, 45, and 52 using in silico. In this study, we develop a novel multiepitope vaccine candidate using an immunoinformatic approach. We predicted the epitopes of the cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) and evaluated their immunogenic properties. Population coverage analysis of qualified epitopes was conducted to determine the successful use of the vaccine worldwide. The epitopes were constructed into a multiepitope vaccine by using AAY linkers between the CTL epitopes and GPGPG linkers between the HTL epitopes. The tertiary structure of the multiepitope vaccine was modeled with AlphaFold and was evaluated by Prosa-web. The results of vaccine construction were analyzed for B-cell epitope prediction, molecular docking with Toll like receptor-4 (TLR4), and molecular dynamics simulation. The results of epitope prediction obtained 4 CTL epitopes and 7 HTL epitopes that are eligible for construction of multiepitope vaccines. Prediction of the physicochemical properties of multiepitope vaccines obtained good results for recombinant protein production. The interaction showed that the interaction of the multiepitope vaccine-TLR4 complex is stable based on the binding free energy value −106.5 kcal/mol. The results of the immune response simulation show that multiepitope vaccine candidates could activate the adaptive and humoral immune systems and generate long-term B-cell memory. According to these results, the development of a multiepitope vaccine with a reverse vaccinology approach is a breakthrough to develop potential cervical cancer therapeutic vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Rizarullah,

Aditama,

Giri-Rachman

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Therefore, we our study focused to developed a potent multi-epitope based vaccine targeting Zika virus. The goal was to develop highly immunogenic vaccine with desirable potential, including nonallergic behavior, nontoxicity, and highly antigenic [ 47 ]…”

Section: Discussionmentioning

confidence: 99%

An immunoinformatics and structural vaccinology approach to design a novel and potent multi-epitope base vaccine targeting Zika virus

Hakami

2024

BMC Chemistry

View full text Add to dashboard Cite

Zika virus is an infectious virus, that belongs to Flaviviridae family, which is transferred to humans through mosquito vectors and severely threatens human health; but, apart from available resources, no effective and secure vaccine is present against Zika virus, to prevent such infections. In current study, we employed structural vaccinology approach to design an epitope-based vaccine against Zika virus, which is biocompatible, and secure and might trigger an adaptive and innate immune response by using computational approaches. We first retrieved the protein sequence from National Center for Biotechnology Information (NCBI) database and carried out for BLAST P. After BLAST P, predicted protein sequences were shortlisted and checked for allergic features and antigenic properties. Final sequence of Zika virus, with accession number (APO40588.1) was selected based on high antigenic score and non-allergenicity. Final protein sequence used various computational approaches including antigenicity testing, toxicity evaluation, allergenicity, and conservancy assessment to identify superior B-cell and T-cell epitopes. Two B-cell epitopes, five MHC-six MHC-II epitopes and I were used to construct an immunogenic multi-epitope-based vaccine by using suitable linkers. A 50S ribosomal protein was added at N terminal to improve the immunogenicity of vaccine. In molecular docking, strong interactions were presented between constructed vaccine and Toll-like receptor 9 (− 1100.6 kcal/mol), suggesting their possible relevance in the immunological response to vaccine. The molecular dynamics simulations ensure the dynamic and structural stability of constructed vaccine. The results of C-immune simulation revealed that constructed vaccine activate B and T lymphocytes which induce high level of antibodies and cytokines to combat Zika infection. The constructed vaccine is an effective biomarker with non-sensitization, nontoxicity; nonallergic, good immunogenicity, and antigenicity, however, experimental assays are required to verify the results of present study.

show abstract

“…The characterization of immunodominant T cell epitopes is lacking for most orthobunyaviruses. Previous studies have primarily observed T cell responses against specific protein subunits, mainly GPC and/or N [ 30 , 31 ]. Immunoinformatic studies have identified and predicted virus-specific CD4+ and CD8+ T cell epitopes within GPC and N for the Jamestown Canyon (JCV), Oropouche Virus (OROV), and Bunyamwera virus (BUNV), showing a high affinity with human major histocompatibility complex class I (MHC-I) and MHC-II ( Table 1 ) [ 30 , 31 , 32 , 33 ].…”

Section: T Cell Responses Against Bunyaviralesmentioning

confidence: 99%

“…Previous studies have primarily observed T cell responses against specific protein subunits, mainly GPC and/or N [ 30 , 31 ]. Immunoinformatic studies have identified and predicted virus-specific CD4+ and CD8+ T cell epitopes within GPC and N for the Jamestown Canyon (JCV), Oropouche Virus (OROV), and Bunyamwera virus (BUNV), showing a high affinity with human major histocompatibility complex class I (MHC-I) and MHC-II ( Table 1 ) [ 30 , 31 , 32 , 33 ]. While these studies suggest the potential development and use of multi-epitope vaccines, future in vivo studies are required to validate immunogenicity, efficacy, and protection.…”

Section: T Cell Responses Against Bunyaviralesmentioning

confidence: 99%

“…Immunoinformatics [32] Glycoproteins YQPTELTRS (716-724) YKAHDKEET (782-790) ILGTGTPKF (1172)(1173)(1174)(1175)(1176)(1177)(1178)(1179)(1180) Immunoinformatics [33] JCV CD8+ N protein AAKAKAALA (26)(27)(28)(29)(30)(31)(32)(33)(34) AALARKPER (152)(153)(154)(155)(156)(157)(158)(159)(160)(161) ADHGESVSL (175)(176)(177)(178)(179)(180)(181)(182)(183) ADHGESVSLS (157)(158)(159)(160)(161)(162)(163)(164)(165) YPLTIGIYRV (108)(109)(110)(111)(112)…”

Section: Peribunyaviridaementioning

confidence: 99%

See 1 more Smart Citation

The Adaptive Immune Response against Bunyavirales

Alatrash,

Herrera

2024

Viruses

View full text Add to dashboard Cite

The Bunyavirales order includes at least fourteen families with diverse but related viruses, which are transmitted to vertebrate hosts by arthropod or rodent vectors. These viruses are responsible for an increasing number of outbreaks worldwide and represent a threat to public health. Infection in humans can be asymptomatic, or it may present with a range of conditions from a mild, febrile illness to severe hemorrhagic syndromes and/or neurological complications. There is a need to develop safe and effective vaccines, a process requiring better understanding of the adaptive immune responses involved during infection. This review highlights the most recent findings regarding T cell and antibody responses to the five Bunyavirales families with known human pathogens (Peribunyaviridae, Phenuiviridae, Hantaviridae, Nairoviridae, and Arenaviridae). Future studies that define and characterize mechanistic correlates of protection against Bunyavirales infections or disease will help inform the development of effective vaccines.

show abstract

Immunoinformatics-based potential multi-peptide vaccine designing against Jamestown Canyon Virus (JCV) capable of eliciting cellular and humoral immune responses

Cited by 12 publications

References 63 publications

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

An immunoinformatics and structural vaccinology approach to design a novel and potent multi-epitope base vaccine targeting Zika virus

The Adaptive Immune Response against Bunyavirales

Contact Info

Product

Resources

About